Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Neoadjuvant BI 765063 with Ezabenlimab or Pembrolizumab in Resectable CRC
NCT05446129Phase 1Terminated
- Sponsor
- Boehringer Ingelheim
- Start
- Sep 2022
- Primary completion
- Aug 2023
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, open-label trial of BI 765063 in colorectal cancer (CRC) (2 arms), sponsored by Boehringer Ingelheim. Primary endpoint: Proportion of Patients With at Least One Occurrence of a Safety or Feasibility Event up to 91 days. Started Sep 2022; status: terminated.
02
Drugs
BI 765063
03
Conditions
colorectal cancer (CRC)
Beyond the preview
Go deeper on NCT05446129.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05446129.